We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Benign Hematology

Journal Scan / Research · September 25, 2020

Rivaroxaban vs Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
Effectiveness and Safety of Rivaroxaban Compared With Low-Molecular-Weight Heparin in Cancer-Associated Thromboembolism
Blood Adv 2020 Sep 08;4(17)4045-4051, OS Costa, CG Kohn, NM Kuderer, GH Lyman, TJ Bunz, CI Coleman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading